Neuropace, Inc. ( (NPCE) ) has released its Q3 earnings. Here is a breakdown of the information Neuropace, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
NeuroPace, Inc., based in Mountain View, California, is a medical device company specializing in innovative solutions for epilepsy, notably through its RNS System, a brain-responsive platform aimed at reducing seizures in patients with drug-resistant epilepsy.
In its third-quarter 2025 earnings report, NeuroPace announced a record quarterly revenue of $27.4 million, marking a 30% increase from the previous year. The company also raised its full-year revenue guidance to between $97 million and $98 million, reflecting strong market performance and strategic advancements.
Key financial highlights include a 31% growth in RNS System revenue and a robust gross margin of 77.4%, driven by a favorable product mix and manufacturing efficiencies. Operating expenses rose to $23.8 million, primarily due to increased sales, marketing, and R&D investments. Despite these expenses, the company reduced its net loss to $3.5 million from $5.5 million a year earlier.
Strategically, NeuroPace is advancing its NAUTILUS study for FDA approval, aiming to expand the RNS System’s indications. The company also submitted its AI-powered Seizure ID application to the FDA, underscoring its commitment to enhancing clinical outcomes and streamlining processes.
Looking ahead, NeuroPace remains optimistic about its growth trajectory, focusing on expanding the adoption of its RNS therapy as a standard care for epilepsy and exploring new opportunities in personalized neuromodulation.